Chung Hun Lee

Dr. Chung Hun Lee

Department of Anesthesiology and Pain Medicine, Korea University Medical Center, Guro Hospital
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in Medicine
Verified
Journal Article
Open access
SCSang Sik Choi
Sang Sik Choi
HKHeezoo Kim
Heezoo Kim
YCYoo Jin Choung
Yoo Jin Choung
SJSung Jin Jeong
Sung Jin Jeong
Chung Hun LeeChung Hun Lee
Chung Hun Lee
Kyphoplasty (KP) has been widely used to treat vertebral compression fractures (VCFs). However, the issue of new VCFs after KP remains controversial. Identification of risk factors for new VCF after KP may help prevent their occurrence in patients. This study aimed to retrospectively determine the major risk factors for new VCF after KP, including those associated with osteoporosis drugs used after kyphoplasty. We reviewed 117 patients who underwent single-level KP. During the follow-up period of 1 year after KP, the demographic data of these patients were compared by dividing them into two groups: those with new fractures (n = 19) and those without new fractures (n = 98). We investigated the age, sex, fracture location, medical history, steroid use history, bone mineral density (BMD), type of osteoporosis treatment, period from fracture to KP, KP method (unilateral or bilateral), bone cement dose, intradiscal cement leakage, preoperative and postoperative compression ratio, kyphotic angle (KA), and lowest vertebral body height in the fractured vertebrae. Based on these data, the factors related to new VCFs after KP were investigated using univariate and multivariate logistic regression analyses. We also investigated whether there were differences in new VCFs according to the type of osteoporosis treatment. During the 1-year follow-up period after KP, the rate of new VCFs was 16.2%. Factors related to new VCFs were BMD, intradiscal cement leakage, KA recovery rate after 1 day, and baseline height in the univariate and multivariate logistic regression analyses. The group treated with zoledronate after KP tended to show a lower frequency of developing new VCFs than the groups treated with alendronate (P = .07), calcium (P = .05), selective estrogen receptor modulator (SERM) (P = .15), and risendronate (P = .02). This study showed that for patients with new VCFs after KP, lower BMD, greater intradiscal cement leakage, greater KA recovery rate, and lower baseline vertebral height were likely risk factors for the development of new VCFs. Additionally, among the drugs used for the treatment of osteoporosis after KP, zoledronate tends to reduce the development of new VCFs compared with other bisphosphonates, SERMs, or calcium.

27 March 2026 in The Korean Journal of Pain
Verified
Journal Article
Open access
PDF file
HKHee Yong Kang
Hee Yong Kang
Chung Hun LeeChung Hun Lee
Chung Hun Lee
DKDoo-Hwan Kim
Doo-Hwan Kim
YKYeon-Dong Kim
Yeon-Dong Kim
WKWon-Joong Kim
Won-Joong Kim
SCSeong-Soo Choi
Seong-Soo Choi
Hee Yong Kang, Chung Hun Lee, Doo-Hwan Kim, Yeon-Dong Kim, Won-Joong Kim, Eunsoo Kim, Jae Hun Kim, Hyun Jung Kim, Yangki Minn, Kyungseung Yang, Jinyoung Oh, Yongjae Yoo, So Young Lim, Mihn-Sook Jue, Eun Joo Choi, Kunhee Han, and Seong-Soo Choi. Korean J Pain -0001;0:. https://doi.org/10.3344/kjp.25161

24 November 2023 in Medicine
Verified
Journal Article
Open access
SPSeongjoo Park
Seongjoo Park
SCSang Sik Choi
Sang Sik Choi
HKHeezoo Kim
Heezoo Kim
SBSang Yoon Byun
Sang Yoon Byun
Chung Hun LeeChung Hun Lee
Chung Hun Lee
Vertebroplasty (VP) effectively treats vertebral compression fractures (VCFs). However, the issue of secondary new VCFs (SNVCFs) after VP is yet to be addressed. Therefore, identification of risk factors for SNVCFs after VP may aid the development of strategies to minimize SNVCF risk. This study aimed to retrospectively evaluate risk factors for SNVCFs after VP, including those associated with the type of anti-osteoporotic treatment administered after VP. Data from 128 patients who underwent single-level VP were collected and reviewed. Patients were divided into 2 groups: those with (n = 28) and without (n = 100) SNVCF within 1 year of VP. We collected the following patient data: age, sex, site of compression fracture, medical history, bone mineral density (BMD), history of long-term steroid use, history of osteoporosis drug use, duration between fracture and VP, VP implementation method (unilateral or bilateral), cement usage in VP, cement leakage into the disc, compression ratio before VP, pre- and postoperative recovery ratio of the lowest vertebral body height, and kyphotic angle of fractured vertebrae. These data were analyzed to identify factors associated with SNVCFs after VP and to investigate the effects of the type of anti-osteoporotic treatment administered for SNVCFs. SNVCFs occurred in 28 patients (21.9%) within 1 year of VP. Logistic regression analysis identified BMD, cement leakage into the disc, and long-term steroid use to be significantly associated with the occurrence of SNVCFs. The group treated with zoledronate after VP had a significantly reduced SNVCF incidence compared with the group treated with calcium (P < .001). In addition, the zoledronate group had a lower SNVCF incidence compared with the groups treated with alendronate (P = .05), selective estrogen receptor modulators (P = .26), or risedronate (P = .22). This study showed that low BMD, presence of an intradiscal cement leak, and long-term steroid use were risk factors for developing SNVCFs following VP. Additionally, among osteoporosis treatments prescribed for VP, zoledronate may be the preferred choice to reduce the risk of SNVCFs.

1 April 2021 in Medicina
Verified
Journal Article
Open access
PDF file
YLYeon Joo Lee
Yeon Joo Lee
MKMyoung Hoon Kong
Myoung Hoon Kong
SCSang Sik Choi
Sang Sik Choi
YKYong Deok Kwon
Yong Deok Kwon
MLMi Kyoung Lee
Mi Kyoung Lee
Chung Hun LeeChung Hun Lee
Chung Hun Lee
New developments in spinal cord stimulation (SCS) have improved the treatment of patients with chronic pain. Although the overall safety of modern SCS has been established, there are no published reports regarding safety considerations when implanting a burst-mode spinal cord stimulator in patients with permanent cardiac pacemakers (PCPs). An 80-year-old man with a complete atrioventricular block implanted with a PCP was considered as a candidate for burst-mode SCS due to well-established postherpetic neuralgia (>180 days after rash). Cardiac monitoring during the burst-mode spinal cord stimulator trial and insertion did not indicate any interference. After the insertion of the burst-mode spinal cord stimulator, the patient showed functional improvement and significant pain relief. The safety of traditional tonic-mode SCS in patients with PCP has been previously reported. This is the first case report describing the safe and effective use of burst-mode SCS in a patient with PCP.

1 September 2021
Verified
Journal Article
Closed access
YKYoung Sung Kim
Young Sung Kim
Chung Hun LeeChung Hun Lee
Chung Hun Lee
AKAh Rahn Kim
Ah Rahn Kim
SCSang Sik Choi
Sang Sik Choi
MLMi Kyoung Lee
Mi Kyoung Lee
SOSeok Kyeong Oh
Seok Kyeong Oh

7 September 2022 in Medicina
Verified
Journal Article
Open access
PDF file
HPHyung Joon Park
Hyung Joon Park
HKHeezoo Kim
Heezoo Kim
SJSung Jin Jeong
Sung Jin Jeong
JLJae Hak Lee
Jae Hak Lee
SCSang Sik Choi
Sang Sik Choi
Chung Hun LeeChung Hun Lee
Chung Hun Lee
Background: Cervical interlaminar epidural steroid injection (CIESI) is increasingly used as an interventional treatment for pain originating from the cervical spine. However, serious neurological complications may occur during CIESI because of direct nerve damage following inappropriate needle placement. Case report: A 35-year-old woman presented with posterior neck pain radiating to the left upper arm. Cervical magnetic resonance imaging (MRI) revealed left C6 nerve impingement. CIESI under fluoroscopic guidance was performed at another hospital using the left C5/6 interlaminar approach. Immediately after the procedure, the patient experienced dizziness, decreased blood pressure, motor weakness in the left upper arm, and sensory loss. She visited our emergency department with postdural puncture headache (PDPH) that worsened after the procedure. Post-admission cervical MRI revealed intramedullary T2 high signal intensity and cord swelling from the C4/5 to C6/7 levels; thus, a diagnosis of spinal cord injury was made. The patient’s PDPH spontaneously improved after 48 h. However, despite conservative treatment with steroids, the decrease in abduction of the left fifth finger and loss of sensation in the dorsum of the left hand persisted for up to 6 months after the procedure. As noticed in the follow-up MRI performed 6 months post-procedure, the T2 high signal intensity in the left intramedullary region had decreased compared to that observed previously; however, cord swelling persisted. Furthermore, left C7/8 radiculopathy with acute denervation was confirmed by electromyography performed 6 months after the procedure. Conclusions: Fluoroscopy does not guarantee the prevention of spinal cord penetration during CIESI. Moreover, persistent neurological deficits may occur, particularly due to intrathecal perforation or drug administration during CIESI. Therefore, in accordance with the recommendations of the Multisociety Pain Workgroup, we recommend performing CIESI at the C6/7 or C7/T1 levels, where the epidural space is relatively large, rather than at the C5/6 level or higher.